Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY2584702 Reference Formulation · 1 trial · 1 indication
The Cmax following a single oral dose of LY2584702 test formulation \[TF (tablet)\] or reference formulation \[RF (capsule)\] is reported.
| Arm | Type | Description |
|---|---|---|
| Part A: 25 mg RF | EXPERIMENTAL | A single 25 mg dose of LY2584702 RF |
| Part A: Placebo | PLACEBO_COMPARATOR | Placebo taken orally |
| Part B: Sequence 1 | EXPERIMENTAL | A single 10 mg dose of LY2584702 TF during the first intervention period, followed by placebo in the second intervention period, followed by a single dose of 50 mg TF in the third intervention period, followed by either an open-label single dose of 50 mg TF after a high fat breakfast (Period 4a) OR placebo or escalated dose of TF in the fasted state (Period 4b). There will be a washout period of at least 3 days between periods. |
| Part B: Sequence 2 | EXPERIMENTAL | Placebo during the first intervention period, followed by a single dose of 50 mg RF in the second intervention period, followed by a single dose of 50 mg TF in the third intervention period, followed by either an open-label single dose of 50 mg TF after a high fat breakfast (Period 4a) OR placebo or escalated dose of TF in the fasted state (Period 4b). There will be a washout period of at least 3 days between periods. |
| Part B: Sequence 3 | EXPERIMENTAL | A single 10 mg dose of LY2584702 TF during the first intervention period, followed by a single dose of 50 mg RF in the second intervention period, followed by a single dose of 50 mg TF in the third intervention period, followed by either an open-label single dose of 50 mg TF after a high fat breakfast (Period 4a) OR placebo or escalated dose of TF in the fasted state (Period 4b). There will be a washout period of at least 3 days between periods. |
| Part B: Sequence 4 | EXPERIMENTAL | A single 10 mg dose of LY2584702 TF during the first intervention period, followed by a single dose of 50 mg RF in the second intervention period, followed by placebo in the third intervention period, followed by either an open-label single dose of 50 mg TF after a high fat breakfast (Period 4a) OR placebo or escalated dose of TF in the fasted state (Period 4b). There will be a washout period of at least 3 days between periods. |
| Name | Type | Description |
|---|---|---|
| LY2584702 Reference Formulation | DRUG | Administered orally |
| LY2584702 Test Formulation | DRUG | Administered orally |
| Placebo | DRUG | Administered orally |
Inclusion Criteria: Male participants: • Agree to use a reliable method of birth control during the study and for at least 1 month following the last dose of study drug Female participants: • Women not of childbearing potential due to surgical sterilization (hysterectomy or bilateral oophorectom...
LY2584702 is an investigational small molecule being studied for the treatment of cancer and for use in healthy participants. It was evaluated in Phase 1 clinical trials, including a study in patients with solid tumors and a single-dose study in healthy participants to assess safety and absorption.
LY2584702 is being developed by Eli Lilly and Company, a pharmaceutical company traded on the NYSE under the ticker symbol LLY. The drug is an investigational small molecule that has been studied in early-stage clinical trials for oncology and healthy participant indications.
LY2584702 is in Phase 1 clinical development. It has completed two Phase 1 trials: one in patients with solid tumors in Japan and another in healthy participants in Singapore. The drug is investigational and not approved for any use.
LY2584702 has been studied in two completed Phase 1 trials. NCT01241461 evaluated the drug in patients with solid tumors in Japan, enrolling 9 participants. NCT01372085 was a single-dose study in healthy participants in Singapore, enrolling 29 participants. Both trials are completed.
LY2584702 is a small molecule being investigated for its potential anti-cancer activity. Its specific molecular target has not been disclosed in the available clinical trial information. The drug was studied in a Phase 1 trial for solid tumors and in a healthy participant study to evaluate its safety and absorption.